ESAs & Cancer Risk in Dialysis: New Anemia Study

New research has highlighted potential safety concerns regarding the use of erythropoiesis-stimulating agents (ESAs) in specific patient populations undergoing dialysis. A case-control study involving 9776 patients examined the association between ESA management of anemia and cancer risk. The findings indicated that high-dose ESA use was associated with higher odds of new cancer development among older patients aged 60 years or older. This data was published in JAMA Network Open.

Study Findings on Dialysis Patients

The investigation focused on patients with kidney failure receiving dialysis. The primary question addressed whether there is an association between erythropoiesis-stimulating agents in the management of anemia and cancer risk. The study design was a case-control analysis. Among the 9776 patients undergoing dialysis, researchers observed specific trends related to dosage and age. High-dose ESA use was linked to higher odds of new cancer development specifically among older patients aged 60 years or older.

These findings contribute to ongoing discussions about the safety profile of anemia treatments in nephrology. Medscape has covered the implications of this research under the headline questioning whether ESAs for anemia raise cancer risk in dialysis patients. The reporting underscores the need for careful evaluation of dosage protocols in vulnerable demographics.

Standard Management of Anemia in CKD and Cancer

Anemia associated with chronic kidney disease (CKD) and cancer is conventionally managed with packed red blood cell (PRBC) transfusions or erythropoietin-stimulating agents (ESAs) like epoetin alfa. Transfusions are limited by complications such as alloimmunization and infection risk. These limitations have led to ESAs becoming the preferred standard of care in many clinical scenarios. Additional therapy may include iron supplementation.

However, iron supplementation potentially causes complications such as iron overload and infection risks in respective patient populations. Clinicians must weigh these factors when determining treatment plans. The preference for ESAs over transfusions is driven by the desire to avoid alloimmunization and infection risks inherent to blood products. Despite this preference, the safety profile of ESAs remains a subject of rigorous review.

Historical Context and Cardiovascular Concerns

The introduction of recombinant human erythropoietin (rhEPO) in 1989 improved anemia management. This development marked a significant shift in how anemia was treated in chronic conditions. However, the widespread use of rhEPO also raised concerns about adverse cardiovascular outcomes in many studies. These historical concerns continue to influence current clinical guidelines and treatment approaches.

Current guidelines promote careful ESA use to balance benefits and risks. The focus is on optimizing hemoglobin targets while minimizing potential adverse effects. Concerns about adverse cardiovascular outcomes and their effects on optimal hemoglobin targets have indicated the need to shift treatment approaches. This shift aims to maintain the benefits of anemia correction without compromising patient safety regarding cardiovascular health or cancer risk.

Review of Emerging Therapies and Trends

A narrative review explored ESA trends, challenges, and emerging therapies for anemia in CKD and cancer patients. The review also examined implications in clinical use. The literature search for this narrative review was conducted on PubMed in January 2025. The search was restricted to articles published between January 2020 and January 2025.

The focus of the review included randomized controlled trials (RCTs), narrative reviews, systematic reviews, and meta-analyses. The initial PubMed search yielded 454 articles. These were subsequently screened according to inclusion and exclusion criteria. The process resulted in a final selection of 58 publications that satisfied the eligibility requirements. This comprehensive analysis provides a broader context for the specific findings observed in the dialysis patient study.

evidence from these studies suggests that ESAs are considerably beneficial in correcting anemia. They are also effective in lowering the need for blood transfusions in adult patients with CKD. However, the balance of benefits and risks requires continuous monitoring. Alternatives like hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) show promise in reducing such adverse effects.

Further clinical experience with agents such as Roxadustat for renal anemia is being documented. Frontiers has published information regarding current clinical experience with Roxadustat. These emerging therapies represent potential shifts in the standard of care. As new data becomes available, treatment protocols may evolve to address the risks identified in earlier generations of erythropoiesis-stimulating agents.

Implications for Clinical Practice

The narrative review summarized the benefits and drawbacks of ESAs as a widely used treatment for anemia of CKD and cancer-related anemia. This summary was published around September 30, 2025. The documentation of both benefits and drawbacks is essential for informed decision-making. Clinicians must consider the age of the patient and the dosage of the agent when prescribing ESAs.

The association between high-dose use and cancer risk in older patients suggests that dosage stratification may be necessary. While ESAs remain a preferred standard of care over transfusions due to infection and alloimmunization risks, the potential for new cancer development in specific groups cannot be ignored. Ongoing research into HIF-PHIs and other alternatives may offer pathways to mitigate these risks while maintaining effective anemia management.